AC
ATRS

Armistice Capital’s Antares Pharma, Inc. ATRS Stock Holding History

Armistice Capital’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-428,000
Closed -$1.16M – 130
2020
Q3 		$1.16M Buy
+428,000
New +$1.18M 0.04% 92
2019
Q4 		– Sell
-5,624,000
Closed -$18.8M – 91
2019
Q3 		$18.8M Sell
5,624,000
-376,000
-6% -$1.24M 1.25% 32
2019
Q2 		$19.7M Sell
6,000,000
-4,300,000
-42% -$12.4M 1.24% 26
2019
Q1 		$31.2M Hold
10,300,000
– – 1.71% 20
2018
Q4 		$28M Buy
10,300,000
+1,180,000
+13% +$3.89M 2.12% 13
2018
Q3 		$30.6M Sell
9,120,000
-2,930,000
-24% -$9.05M 1.84% 22
2018
Q2 		$31.1M Sell
12,050,000
-510,000
-4% -$1.27M 2.03% 17
2018
Q1 		$27.6M Buy
12,560,000
+4,960,000
+65% +$11.2M 2.11% 20
2017
Q4 		$15.1M Buy
7,600,000
+3,400,000
+81% +$7.4M 1.51% 20
2017
Q3 		$13.6M Sell
4,200,000
-1,500,000
-26% -$4.63M 1.6% 20
2017
Q2 		$18.4M Sell
5,700,000
-3,000,000
-34% -$8.5M 2.34% 13
2017
Q1 		$24.7M Sell
8,700,000
-2,300,000
-21% -$5.53M 5.1% 2
2016
Q4 		$25.6M Sell
11,000,000
-1,300,000
-11% -$2.48M 6.06% 2
2016
Q3 		$20.7M Sell
12,300,000
-3,130,000
-20% -$3.83M 6.63% 2
2016
Q2 		$16.2M Buy
15,430,000
+24,297
+0.2% +$23.5K 6.17% 2
2016
Q1 		$13.4M Buy
15,405,703
+2,165,703
+16% +$2.1M 5.26% 2
2015
Q4 		$16M Buy
13,240,000
+4,940,000
+60% +$6.87M 5.72% 2
2015
Q3 		$14.1M Buy
8,300,000
+1,900,000
+30% +$3.72M 4.82% 5
2015
Q2 		$13.3M Buy
6,400,000
+2,600,000
+68% +$6.3M 4.78% 6
2015
Q1 		$10.3M Buy
3,800,000
+1,200,000
+46% +$3.04M 4.56% 8
2014
Q4 		$6.68M Buy
+2,600,000
New +$5.84M 3.21% 18

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Armistice Capital's ATRS Position: Q4 2020 in Review

Armistice Capital sold out of Antares Pharma, Inc. (ATRS) in Q4 2020, closing a stake of 428,000 shares — an estimated $1.16M sold.

Armistice Capital first reported a position in ATRS in Q4 2014 and held it in 21 quarters. The position peaked at $31.2M in Q1 2019. 174 funds tracked by Wall St. Rank hold ATRS as of Q4 2020.

  • Armistice Capital reported no remaining Antares Pharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Armistice Capital sold 428,000 Antares Pharma, Inc. shares in Q4 2020, an estimated $1.16M.
  • Armistice Capital first reported a position in Antares Pharma, Inc. in Q4 2014 and held it in 21 quarters.
  • Armistice Capital's Antares Pharma, Inc. position peaked at $31.2M in Q1 2019.
  • 174 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2020.

Based on Armistice Capital's 13F filing for Q4 2020, filed 16 Feb 2021.